Inventor · disambiguated record
Darby Schmidt
Also filed as: SCHMIDT DARBY · SCHMIDT DARBY R · SCHMIDT DARBY RYE
20 granted patents·31 pending applications·204 citations·filing 2004–2024
95Inventor score
Files withSYROS PHARMACEUTICALS INC16FLAGSHIP PIONEERING INNOVATIONS V INC6BALOGLU ERKAN5CARAWAY THERAPEUTICS INC3RAGHAVAN SUBHAREKHA3
Top patents by PatentIndex Score
51 records- 0196US9902728B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Feb 27, 2018·24 cites·40 claims
- 0295US10934299B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Mar 2, 2021·7 cites·20 claims
- 0395US10377760B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·17 cites·20 claims
- 0493US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0592US10336760B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jul 2, 2019·11 cites·21 claims
- 0692US10059690B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·9 cites·19 claims
- 0792US7301036B2Cyclic guanidines, compositions containing such compounds and methods of useMERCK & CO INC·Filed 2004·Granted Nov 27, 2007·45 cites·20 claims
- 0891US10047070B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2014·Granted Aug 14, 2018·17 cites·19 claims
- 0989US8981084B2Oxadiazole HDAC inhibitorsBALOGLU ERKAN·Filed 2011·Granted Mar 17, 2015·19 cites·7 claims
- 1086US10308648B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·6 cites·20 claims
- 1185US10106526B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·5 cites·19 claims
- 1284US10906889B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Feb 2, 2021·4 cites·32 claims
- 1384US10519135B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·3 cites·18 claims
- 1483US8901156B2Compounds and methodsBALOGLU ERKAN·Filed 2011·Granted Dec 2, 2014·8 cites·22 claims
- 1583US8741910B2Soluble guanylate cyclase activatorsBROCKUNIER LINDA L·Filed 2009·Granted Jun 3, 2014·12 cites·20 claims
- 1679US10865206B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·1 cites·25 claims
- 1779US9284301B2Soluble guanylate cyclase activatorsSCHMIDT DARBY·Filed 2011·Granted Mar 15, 2016·9 cites·4 claims
- 1877US2025388911A1Thanotransmission polypeptides and their use in treating cancerFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2024·Application pending·0 cites
- 1972US12018030B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Jun 25, 2024·0 cites·16 claims
- 2072US2021107912A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2172US2024360165A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2271US2021221814A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALIS INC·Filed 2020·Application pending·0 cites
- 2366US2022325287A1Thanotransmission polypeptides and their use in treating cancerFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2022·Application pending·0 cites
- 2465US2021061803A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2565US2020010473A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2665US2019330218A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2761US2023062491A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2861US2025136606A1Modulators of trpml, their compositions and methods of useCARAWAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2961US2024398812A1Modulators of trpml, their compositions and methods of useCARAWAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3060US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3159US2024299348A1Modulators of trpml, their compositions and methods of useCARAWAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3258US2024316104A1Immune cells engineered to promote thanotransmission and uses thereofFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2022·Application pending·0 cites
- 3355US2024058279A1Use of cell turnover factors for increasing tissue regenerationFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2021·Application pending·0 cites
- 3454US2023355804A1Viruses engineered to promote thanotransmission and their use in treating cancerFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2021·Application pending·0 cites
- 3553US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3653US2015038534A1Compounds and methodsTEMPERO PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3751US8637555B2Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofSEMPLE GRAEME·Filed 2004·Granted Jan 28, 2014·0 cites·2 claims
- 3851US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3948US8168649B2Niacin receptor agonists, compositions containing such compounds and methods of treatmentRAGHAVAN SUBHAREKHA·Filed 2006·Granted May 1, 2012·0 cites·20 claims
- 4048US2023114107A1Combination anti-cancer therapies with inducers of iron-dependent cellular disassemblyFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 4146US2007072924A1Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofSEMPLE GRAEME·Filed 2006·Application pending·0 cites
- 4245US2009170891A1Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of TreatmentCOLLETTI STEVEN L·Filed 2007·Application pending·0 cites
- 4343US2014256740A1Compounds and methodsTEMPERO PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 4442US2012178750A1Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of TreatmentRAGHAVAN SUBHAREKHA·Filed 2012·Application pending·0 cites
- 4541US2009042926A1Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of TreatmentIMBRIGLIO JASON·Filed 2006·Application pending·0 cites
- 4641US2014315881A1Compounds and methodsTEMPERO PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 4741US2014155419A1Compounds and methodsBALOGLU ERKAN·Filed 2012·Application pending·0 cites
- 4839US2014155381A1Compounds and methodsBALOGLU ERKAN·Filed 2012·Application pending·0 cites
- 4939US2009054423A1Niacin receptor agonists, compositions containing such compounds and methods of treatmentIMBRIGLIO JASON E·Filed 2006·Application pending·0 cites
- 5039US2009062269A1Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of TreatmentRAGHAVAN SUBHAREKHA·Filed 2007·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →